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Introduction
Transcription factor 4 (TCF4) is an E-protein basic helix–
loop–helix (bHLH) transcription factor that binds to the 
Ephrussi-box (E-Box) DNA motif.1,2 Common variants in the 
TCF4 gene are among the most robustly supported genetic 
risk factors for schizophrenia.3–6 Rare TCF4 deletions and 
loss-of-function point mutations cause Pitt–Hopkins syn-
drome,7–11 a developmental disorder associated with severe 
intellectual disability.
E-proteins show widespread expression and act as tran-
scriptional activators or repressors by forming heterodimers 
with other bHLH proteins.1 TCF4 is highly expressed in the 
fetal as well as adult human brain12,13 and is known to dimer-
ize with several bHLH factors that are important for neural 
development.14–16 Knockout of the TCF4 gene has been re-
ported to affect the differentiation of specific neuronal popu-
lations in the mouse hindbrain.15 However, data pertaining 
to the role of TCF4 in human neural development are cur-
rently lacking.
Experimental knockdown of TCF4 expression in human 
neuroblastoma-derived cells (SH-SY5Y) has been found to al-
ter the expression of genes involved in transforming growth 
factor (TGF)-β signalling, epithelial to mesenchymal transition 
and apoptosis.17 Stable knockdown of TCF4 in neural progeni-
tor cells from the human fetal midbrain has been reported to 
result in gene expression changes more characteristic of differ-
entiating than proliferating cells, suggesting effects on the 
timing of neural differentiation.18 However, to date, effects of 
TCF4 manipulation in cells from the developing human cere-
bral cortex have not been explored. In the present study, we 
experimentally reduced the endogenous expression of TCF4 
in a neural progenitor cell line derived from human fetal neo-
cortex in order to explore molecular and cellular mechanisms 
through which TCF4 perturbation could interfere with early 
cortical development.
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Background: Common variants in the TCF4 gene are among the most robustly supported genetic risk factors for schizophrenia. Rare 
TCF4 deletions and loss-of-function point mutations cause Pitt–Hopkins syndrome, a developmental disorder associated with severe 
 intellectual disability. Methods: To explore molecular and cellular mechanisms by which TCF4 perturbation could interfere with human 
cortical development, we experimentally reduced the endogenous expression of TCF4 in a neural progenitor cell line derived from the 
developing human cerebral cortex using RNA interference. Effects on genome-wide gene expression were assessed by microarray, fol-
lowed by Gene Ontology and pathway analysis of differentially expressed genes. We tested for genetic association between the set of 
differentially expressed genes and schizophrenia using genome-wide association study data from the Psychiatric Genomics Consortium 
and competitive gene set analysis (MAGMA). Effects on cell proliferation were assessed using high content imaging. Results: Genes 
that were differentially expressed following TCF4 knockdown were highly enriched for involvement in the cell cycle. There was a nonsig-
nificant trend for genetic association between the differentially expressed gene set and schizophrenia. Consistent with the gene expres-
sion data, TCF4 knockdown was associated with reduced proliferation of cortical progenitor cells in vitro. Limitations: A detailed mech-
anistic explanation of how TCF4 knockdown alters human neural progenitor cell proliferation is not provided by this study. Conclusion: 
Our data indicate effects of TCF4 perturbation on human cortical progenitor cell proliferation, a process that could contribute to cognitive 
deficits in individuals with Pitt–Hopkins Syndrome and risk for schizophrenia.
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Methods
Cell culture
Experiments were performed using a neural progenitor cell 
line (CTX0E03) derived from the cortical neuroepithelium of 
a 12-week human fetus obtained from ReNeuron Ltd (www 
.reneuron.com) under a material transfer agreement. This cell 
line has been conditionally immortalized by genomic incor-
poration of the c-MycERTAM  transgene, to stimulate prolifera-
tion in the presence of the synthetic drug 4-hydroxy- 
tamoxifen (4-OHT). The derivation and characteristics of the 
CTX0E03 cell line are described in detail by Pollock and col-
leagues.19 Cells were cultured on laminin-coated T75 flasks 
using a modified DMEM:F12 media, as described previ-
ously.20 For the RNA interference experiments, 4-OHT was 
excluded from the media so that proliferation was not artifi-
cially stimulated through c-Myc overexpression.
RNA interference in cultured cells
Two nonoverlapping small interfering RNA (siRNA) target-
ing all TCF4 messenger RNA (mRNA) transcripts defined by 
Sepp and colleagues13 were used as 2 separate TCF4 siRNA 
conditions. The first condition (Cat #s13863) has the sense se-
quence 5’-GCUCUGAGAUCAAAUCCGAtt-3’ and targets 
exon 18 of full-length TCF4, as denoted by Sepp and col-
leagues.13 The second condition (Cat #s13864) has the sense 
sequence 5’-GAAGGACCCUUACACUCUUtt-3’ and targets 
exon 15. We used a negative control siRNA (Silencer Nega-
tive Control #1, Life Technologies, Cat #AM4611) with no se-
quence similarity with any human transcript for the control 
comparison condition. For the microarray experiment, each 
siRNA was combined with N-TER transfection reagent 
(Sigma-Aldrich) and added to 4 T75 flasks of separately 
seeded cells at a final siRNA concentration of 10 nM. For the 
cell proliferation experiments, each siRNA was combined 
with N-TER transfection reagent and added to 12  wells 
(0.33 cm2) of separately seeded cells at a final siRNA concen-
tration of 10 nM. In order to estimate transfection efficiency, 
an additional T75 flask of seeded cells was transfected with 
10 nM BLOCK-iT™ Alexa Fluor Red Fluorescent Control oli-
gonucleotide (Life Technologies) using the same N-TER 
 reagent and visualized after 24 h using fluorescence micros-
copy. Media (minus both 4-OHT and siRNA) was replaced 
48 h after transfection.
RNA and protein preparation
Cells from each T75 flask were harvested for RNA and pro-
tein 96 hours after siRNA transfection. Total RNA was ex-
tracted from half of the cells in each flask using Tri-Reagent 
(Life Technologies) according to manufacturer’s instructions. 
We assessed the integrity of total RNA using the Agilent 2100 
Bioanalyzer (Agilent Technologies). All samples had an RNA 
integrity number (RIN) above 9.5. Protein was extracted from 
the remaining half of the cells in each flask using radioim-
munoprecipitation assay (RIPA)  buffer.
Assessment of TCF4 RNA knockdown
Quantitative polymerase chain reaction (qPCR) was used to as-
sess the level of TCF4 RNA knockdown in each TCF4 siRNA 
condition (relative to the control siRNA condition) before 
 genome-wide gene expression profiling. Total RNA was treated 
with Turbo DNA-free (Life Technologies) and converted to 
complementary DNA (cDNA) using random decamers and 
 SuperScript III (Life Technologies). The qPCR primers were de-
signed to amplify exonic sequence included in all known TCF4 
transcripts: F: 5’-GAAAGCTGCGTGTCTGAAAA-3’ and 
5’-CATCTGTCCCATGTGATTCG-3’. We measured expression 
of GAPDH, HPRT1 and RPL13A simultaneously as internal con-
trol genes. The expression of these 3 housekeeping genes was 
subsequently found not to differ between siRNA and control 
conditions in either cell line in the microarray data (all p > 0.05). 
Reactions were performed using FIREPol EvaGreen qPCR Mix 
(Solis Biodyne), an MJ Research Chromo 4 (Bio-Rad) and MJ 
Opticon Monitor analytic software (Bio-Rad). We performed 
duplicate qPCR reactions to measure expression of each gene in 
each cDNA sample. Expression of each gene was measured 
against a standard curve constructed by serial dilution of pooled 
cDNA. Mean measures of TCF4 expression were divided by the 
geometric average of the mean measures for the 3 internal con-
trol genes to yield a normalized TCF4 expression value for each 
sample. We compared normalized TCF4 expression values be-
tween each TCF4 siRNA condition and the negative control 
siRNA condition using t tests (2-tailed).
Assessment of TCF4 protein knockdown
Supernatant from whole-cell lysates was mixed with an equal 
volume of 2X Laemmli buffer and heated to 100°C for 5 min. 
Equal volumes of 3 samples from each condition were then 
loaded and separated on a 10% polyacrylamide gel by stan-
dard SDS–PAGE. The gel was blotted and probed for TCF4 
protein using a C-terminal antibody produced in rabbit 
(Sigma-Aldrich #SAB4502928) and for β-actin protein using a 
monoclonal antibody produced in mouse (Abcam #ab8226), 
with fluorescent secondary antibodies to each. The blot was 
imaged and densitometry performed using a near infrared 
Odyssey scanner. TCF4 immunoreactivity values were nor-
malized to β-actin values within blot and compared between 
TCF4 and control siRNA conditions using t tests (2-tailed).
Genome-wide gene expression profiling and pathway 
 analysis
We performed genome-wide gene expression profiling of the 
12 total RNA samples (4 samples for each siRNA targeting 
TCF4 and 4 samples for the control siRNA) using the Illumina 
TotalPrep RNA amplification kit and Illumina HT-12 v4 Bead-
Chip arrays. Data were extracted from GenomeStudio soft-
ware (Illumina), and we applied variance stabilizing transfor-
mation followed by robust spline normalization using the lumi 
Bioconductor package.21 All microarray data from this study 
have been submitted to the Gene Expression Omnibus (www 
.ncbi.nlm.nih.gov/geo/), with the accession number GSE62085.
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Microarray probes showing nominally significant (p < 0.05, 
uncorrected) differences between each TCF4 siRNA condition 
and the control siRNA condition were first identified using in-
dividual t tests (2-tailed) on normalized microarray data. To 
limit spurious results arising from low expression genes, we ex-
cluded probes that were not detected in all 12 samples with a 
detection p < 0.05. To refine the data set to those changes most 
likely to reflect TCF4 knockdown rather than off-target effects 
of individual TCF4 siRNA, we identified gene expression 
changes that were significant (p < 0.05) in both TCF4 siRNA 
conditions and occurred in the same direction (i.e., up- or 
downregulation) relative to the control siRNA condition. We 
additionally used Significance Analysis of Microarrays (SAM) 
software22 to identify high-confidence gene expression changes 
between each TCF4 siRNA condition and the control siRNA 
condition, selecting those with a false discovery rate (FDR) < 
0.05 and again identifying those changes shared by both siRNA 
conditions in the same direction relative to the control siRNA. 
We used the hypergeometric probability test, as used by Rosen 
and colleagues,23 to assess the probability of the differentially 
expressed gene lists shared by the 2 siRNA conditions occur-
ring by chance, based on the number of differentially expressed 
gene probes associated with each siRNA and the number of 
probes that had a detection p < 0.05 in all samples. The gene set 
shared by the 2 TCF4 siRNA conditions was subject to Gene 
Ontology (GO) and KEGG pathway analysis through the 
 DAVID Bioinformatics Resource 6.7,24 which uses a modified 
Fisher exact test to assess enrichment within predefined gene 
sets. We tested for enrichment of differentially expressed genes 
within all KEGG pathways and biological process terms under 
the comprehensive GOTERM_BP_FAT category, using all gene 
probes that had a detection p < 0.05 in all samples as the back-
ground comparison. We tested for genetic association between 
schizophrenia and the set of differentially expressed genes 
shared by the 2 TCF4 siRNA conditions (at p < 0.05) using the 
latest genome-wide association study (GWAS) data from the 
Psychiatric Genomics Consortium6 and MAGMA25 for compet-
itive gene set analysis. Summary schizophrenia GWAS statis-
tics were downloaded from www.med.unc.edu/pgc/results-
and-downloads. MAGMA was run with default settings and 
no gene extension window. We excluded TCF4 from these 
analyses in order to avoid artificial inflation of the genetic asso-
ciation with schizophrenia.
Confirmation of selected gene expression changes
We used qPCR to confirm altered RNA expression of selected 
genes involved in the cell cycle. Genes were selected on the 
basis of exhibiting at least a 30% mean difference in expres-
sion between each TCF4 siRNA condition and the control 
siRNA condition in the microarray data. DNAse-treated RNA 
used for genome-wide expression profiling was converted to 
cDNA using random decamers and SuperScript III (Life Tech-
nologies). The qPCR primers were designed to target the 
same exons as the microarray probes showing differential ex-
pression between siRNA conditions. The microarray data 
from all samples were used to select an appropriate internal 
control gene for these assays, as performed previously.20,26 
ATP5B was hereby chosen as a suitable internal control be-
cause it had the smallest coefficient of variation across sam-
ples, it had no significant differences between siRNA condi-
tions, the probe mapped to a single genomic site and it was 
possible to design primers targeting the same exon as the 
probe. All primer sequences are shown in Appendix 1, 
Table S1, available at jpn.ca. Reactions were carried out in 
triplicate for each sample using FIREPol EvaGreen qPCR Mix 
(Solis Biodyne) and measured against a standard curve for 
each gene, as described above.
Cell proliferation assay
Ninety-six hours after siRNA transfection, 10  uM bromo-
deoxyuridine (BrdU; Sigma-Aldrich) was added to each of the 
12 wells of seeded cells for the TCF4 siRNA#1, TCF4 siRNAi#2 
and negative control siRNA conditions and incubated for 6 h. 
Cells were then fixed in 2% paraformaldehyde, permeabilized 
and incubated overnight with a rabbit antibody against Ki67 
(Abcam # ab15580; 1:500 dilution) and a rat antibody against 
BrdU (AbD Serotech # MCA2060; 1:500 dilution). The second-
ary antibodies were Alexa Fluor 594 Donkey Anti-Rabbit IgG 
and Alexa Fluor 488 Donkey Anti-Rat IgG (Life Technologies 
#A21207 and #A21208). Cell nuclei were stained by incubation 
with DAPI (1:1000 dilution).
Image acquisition was performed using the CellInsight 
NXT High Content Screening Platform (Thermo Scientific) 
with a 10× objective lens. Image processing and downstream 
analysis was conducted using the iDEV software package. We 
used DAPI-stained nuclei to determine valid objects (cells), 
with objects being excluded based on size and proximity to 
the edge of the field. We used segmentation to resolve 
clumped nuclei. Images were acquired for a total of 6 fields 
per well. Control wells lacking primary antibody were used to 
set background fluorescence levels. We identified BrdU- and 
ki67-positive nuclei using the Target Activation bioapplica-
tion included in the iDEV software. The average percentage of 
BrdU- and ki67-positive cells was calculated from the 6 ac-
quired images for each well. The percentages of BrdU- and 
ki67-positive cells in the 12 wells of each TCF4 siRNA condi-
tion were then compared with those in the 12 wells of the neg-
ative control siRNA condition using t tests (2-tailed).
Results
We used 2 nonoverlapping siRNA conditions (TCF4 siRNA #1 
and siRNA #2) to transiently knock down TCF4 in cultured 
neural progenitor cells derived from human fetal neocortex. 
Transfection efficiency, as indexed by uptake of BLOCK-iT 
 Alexa Fluor Red Fluorescent Control oligonucleotide, was esti-
mated to be above 80% (Fig. 1A). At harvest, mean TCF4 RNA 
expression (as indexed by qPCR) was reduced by 57% (p < 
0.001) in the TCF4 siRNA #1 condition and 42% (p < 0.001) in 
the TCF4 siRNA #2 condition relative to the control siRNA 
condition (Fig. 1B). Mean TCF4 protein expression, as indexed 
by Western blot, was reduced by 35% (p = 0.018) in the TCF4 
siRNA #1 condition and 31% (p = 0.05) in the TCF4 siRNA #2 
condition relative to the control siRNA condition (Fig. 1C).
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Gene expression differed significantly (p < 0.05) between the 
TCF4 siRNA #1 condition and the control siRNA condition at 
1753 microarray probes and between the TCF4 siRNA #2 condi-
tion and the control siRNA condition at 1480 microarray probes. 
Nominally significant gene expression differences were shared 
by the 2 TCF4 siRNA conditions in the same direction relative to 
the control condition at 628 probes. This overlap of gene expres-
sion changes was highly significant (p < 1 × 10–200). The full list of 
nominally significant gene expression changes shared by both 
TCF4 siRNA conditions is provided in Appendix 1, Table S2. A 
smaller number of directional gene expression changes were 
shared by the 2 TCF4 siRNA conditions relative to the control 
siRNA condition at FDR < 0.05. This more stringent analysis 
identified high- confidence gene expression changes at 39 gene 
probes that were shared by both TCF4 siRNA conditions 
(Table 1), an overlap that was highly significant (p = 2.2 × 10–58).
The GO analysis of the shared set of 628 differentially ex-
pressed gene probes (p < 0.05) showed a highly significant 
enrichment of genes involved in the cell cycle. The most sig-
nificant GO term was “M-Phase” (p = 6.3 × 10–10, Bonferroni-
corrected), with the majority of other significant GO terms 
also relating to the cell cycle (Appendix 1, Table S3). Consis-
tent with the GO analysis, the only significant KEGG term to 
survive Bonferroni correction was “cell cycle” (p = 0.006, 
 Bonferroni-corrected; Fig. 2). A similar enrichment of the 
KEGG cell cycle pathway (p = 0.004, Bonferroni-corrected) 
was observed in the smaller set of 39 genes that were differ-
entially expressed between the control siRNA and each TCF4 
siRNA condition at an FDR < 0.05. We confirmed altered ex-
pression of selected cell cycle genes showing expression 
changes following TCF4 knockdown (CDCA3, MAD2L1, 
MCM5 and PCNA) by qPCR (Appendix 1, Fig. S1).
Given that variation in the TCF4 gene confers susceptibility 
to schizophrenia, we tested for genetic association between the 
set of genes that were differentially expressed following TCF4 
knockdown (at p < 0.05) and schizophrenia using large-scale 
Fig. 1: Knockdown of TCF4 by RNA interference in the CTX0E03 neural progenitor cell line. (A) Uptake of Red Fluorescent oligonucleo-
tide into CTX0E03 neural progenitor cells as an index of small interfering RNA (siRNA) transfection efficiency. Picture taken 24 h after 
transfection using an Olympus I×70 inverted microscope and AxioVision 4.8 Imaging software (Zeiss). Transfection efficiency was thus 
 estimated to be above 80%. (B) TCF4 RNA expression, as indexed by quantitative polymerase chain reaction (qPCR) at cell harvest (n = 4 
per condition). Mean TCF4 RNA expression was reduced by 57% (p < 0.001) in the TCF4 siRNA #1 condition and 42% (p < 0.001) in the 
TCF4 siRNA #2 condition relative to the control siRNA condition. C) TCF4 protein expression, as indexed by Western blot, at cell harvest 
in 3 samples from each condition. TCF4 protein, indicated by a band of ~71kDa (i), was reduced by 35% (p = 0.018) in the 3 samples of 
the TCF4 siRNA #1 condition and 31% (p = 0.05) in 3 samples of the TCF4 siRNA #2 condition relative to those of the control siRNA con-
dition (ii). Error bars represent standard errors of the mean.
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GWAS data.6 Competitive gene set analysis using MAGMA in-
dicated a nonsignificant trend (p = 0.06) for genetic association 
between this gene set and the disorder. Notably, 5 of the 9 dif-
ferentially expressed genes showing the most significant associ-
ation with schizophrenia (gene-based p < 1 × 10-5) in the 
MAGMA analysis (GNL3, STAG1, CENPM, NCAPD3 and 
CDC20) have known roles in the cell cycle. MAGMA-generated 
schizophrenia association p values for all differentially ex-
pressed genes are provided in Appendix 1, Table S4.
We investigated whether TCF4 siRNA conditions are associ-
ated with effects on the proliferation of human cortical progeni-
tor cells in vitro in further experiments using high- content 
screening. Results are shown in Figure 3. In the TCF4 siRNA#1 
condition, we observed a mean 33% decrease in Ki67-positive 
cells (p < 0.001) and a mean 34% decrease in BrdU-positive cells 
(p = 0.017) compared with the negative control siRNA. In the 
TCF4 siRNA#2 condition, we observed a mean 28% decrease 
in Ki67-positive cells (p = 0.010) and a mean 35% decrease in 
BrdU-positive cells (p = 0.027) compared with the negative 
control siRNA condition.
Discussion
In order to explore early neurodevelopmental processes 
through which genetic perturbation of TCF4 could increase the 
risk for schizophrenia and Pitt–Hopkins syndrome, we have 
Table 1: High-confidence gene expression changes observed at a false discovery rate < 0.05 in both TCF4 siRNA 
conditions compared with the control siRNA condition
Gene Microarray probe Fold-change siRNA#1 q-value siRNA#1 Fold-change siRNA#2 q-value siRNA#2
ALDOC ILMN_1755974 0.67 0.00 0.67 0.00
CLIP3 ILMN_1789733 0.64 0.00 0.67 0.00
CRYAB ILMN_1729216 0.50 0.00 0.56 0.00
LOC100008588 ILMN_3243593 0.52 0.00 0.56 0.00
LOC100008589 ILMN_3251587 0.38 0.00 0.37 0.00
RNF19A ILMN_1812327 0.65 0.00 0.62 0.00
TCF4 ILMN_1814194 0.53 0.00 0.61 0.00
IGDCC3 ILMN_1744635 0.70 1.97 0.68 0.00
PNCK ILMN_1697189 0.75 1.97 0.69 0.00
LOC100132394 ILMN_3249578 0.70 3.03 0.59 0.00
APOD ILMN_1780170 0.70 0.00 0.70 3.95
BNIP3 ILMN_1724658 0.69 0.00 0.68 3.95
LOC100134364 ILMN_3246805 0.64 0.00 0.62 3.95
DDX10 ILMN_1753249 1.67 0.00 1.40 4.96
EDNRB ILMN_1751904 0.62 0.00 0.71 4.96
FREM2 ILMN_1703174 0.67 0.00 0.72 4.96
KLF9 ILMN_1778523 0.73 1.97 0.72 3.95
TTYH1 ILMN_1758497 0.73 1.97 0.70 3.95
NTS ILMN_1764690 1.58 1.97 1.43 4.96
SLC22A18 ILMN_2382505 0.73 3.03 0.69 3.95
BIRC5 ILMN_2349459 1.41 3.03 1.44 4.96
HMMR ILMN_2409220 1.37 3.03 1.39 4.96
LOC100131609 ILMN_3292224 1.44 3.03 1.44 4.96
MCM4 ILMN_1737205 1.46 3.03 1.54 4.96
PCDH20 ILMN_1703572 1.43 3.03 1.45 4.96
HMGB2 ILMN_1654268 1.37 3.76 1.54 4.96
KDELC2 ILMN_1651557 1.39 3.76 1.42 4.96
LOC651816 ILMN_1729115 1.53 3.76 1.53 4.96
SPC24 ILMN_2181432 1.39 3.76 1.50 4.96
UBE2C ILMN_2301083 1.35 3.76 1.38 4.96
ADAM19 ILMN_1713751 0.75 4.62 0.70 3.95
CDC45 ILMN_1670238 1.40 4.62 1.41 4.96
HSPH1 ILMN_1712888 1.38 4.62 1.46 4.96
LOC148915 ILMN_1776052 1.34 4.62 1.38 4.96
LOC402112 ILMN_3213568 1.38 4.62 1.38 4.96
MAD2L1 ILMN_1777564 1.38 4.62 1.42 4.96
MCM5 ILMN_1815169 1.30 4.62 1.39 4.96
NUSAP1 ILMN_2409298 1.31 4.62 1.47 4.96
PCNA ILMN_1694177 1.36 4.62 1.39 4.96
siRNA = small interfering RNA.
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performed genome-wide expression profiling of a human cor-
tical progenitor cell line following TCF4 knockdown. We found 
that TCF4 knockdown resulted in altered expression of genes in-
volved in cell cycling. Consistent with the gene expression data, 
TCF4 siRNA conditions were associated with decreased cortical 
progenitor cell proliferation in vitro. These data implicate TCF4 
in the regulation of human cortical progenitor cell proliferation, 
a mechanism that could contribute to neurodevelopmental fea-
tures of schizophrenia and Pitt–Hopkins syndrome.
TCF4 has been previously implicated in neural progenitor 
cell proliferation in the mouse, where it has been shown to be 
a genomic target of the zinc finger protein Zac1.27 TCF4 has 
also been found to participate in the induction of cell cycle ar-
rest in human colorectal cancer cell lines.28 In a study by 
Chen and colleagues,18 stable knockdown of TCF4 in a neural 
progenitor cell line derived from the human fetal ventral 
midbrain brought about changes in gene expression charac-
teristic of differentiating rather than proliferating cells. 
 Although no effect on cell proliferation was observed, the 
 authors speculated that reduced dosage of TCF4 could result 
in precocious differentiation of some neural progenitors that 
had prematurely exited the cell cycle.18
The neural progenitor cell line we used for this study was 
derived from the cortical neuroepithelium of a 12-week 
 human fetus.19 This cell line has been shown to differentiate 
into β-III tubilin-positive neurons and GFAP-positive astro-
cytes following removal of 4-OHT and the growth factors 
bFGF and EGF.19 Although we performed our experiments 
while these cells were in a proliferative state with growth fac-
tors (but not 4-OHT) present, our previous work using the 
same cell line under similar conditions has shown that gene 
perturbations do not necessarily affect the expression of cell 
cycle genes. Thus, our knockdown of the schizophrenia sus-
ceptibility gene ZNF804A was found to result in gene expres-
sion changes that were enriched for the GO term “cell adhe-
sion,”20 while manipu lation of miR-137 caused gene 
expression changes that were most significantly enriched for 
the GO term “neuronal differentiation.”26 Although the gene 
expression changes we observed following TCF4 knockdown 
were highly enriched for involvement in the cell cycle, differ-
entially expressed genes shared by the 2 TCF4 siRNA condi-
tions (Table 1 and Appendix 1, Table S2) include many re-
lated to various other functions in both the developing and 
mature brain.
Fig. 2: Enrichment of gene expression changes (p < 0.05) shared by the TCF4 small interfering RNA (siRNA)#1 and TCF4 siRNA#2 condi-
tions in the “cell cycle” KEGG pathway (p = 0.006, Bonferroni-corrected). Genes exhibiting altered expression in association with both TCF4 
siRNA conditions are indicated in pink. Image generated through the DAVID Bioinformatics Resource 6.724
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At present, our knockdown of TCF4 expression in human 
neural progenitor cells is most clearly relevant to Pitt– 
Hopkins syndrome. Although recent studies indicate diverse 
mechanisms by which Pitt–Hopkins syndrome–associated 
missense mutations in the TCF4 gene impair TCF4 func-
tion,10,11 haploinsufficiency of TCF4 resulting from large 
 heterozygous deletions encompassing the gene is a well- 
established cause of the disorder.7–9 Importantly, the effects 
of these deletions are likely to become apparent as soon as 
TCF4 is expressed. Effects on TCF4 expression are also likely 
to mediate associations between schizophrenia and common 
noncoding variants at the TCF4 locus.3–6 However, it is cur-
rently unknown when these variants exert their effects and 
which TCF4 transcripts are affected. Immature neurons de-
rived from induced pluripotent stem cells from individuals 
with schizophrenia have been found to exhibit increased 
TCF4 RNA expression compared with those derived from 
healthy controls,29 suggesting that early developmental dis-
turbances in TCF4 expression are relevant to the disorder. 
Increased TCF4 RNA expression in fibroblasts and blood 
from adults with schizophrenia30 and psychosis31 has also 
been reported.
Although alternative cellular functions of TCF4 could 
 mediate its genetic association with schizophrenia,32 docu-
mented effects of other high-confidence schizophrenia sus-
ceptibility genes on cell proliferation33,34 support this as a 
neurobiological risk mechanism for the disorder. Several of 
the differentially expressed genes showing most significant 
association with schizophrenia in the present MAGMA 
analy sis have known roles in cell cycling, suggesting that 
TCF4 could operate through a network of other susceptibil-
ity genes involved in neural cell proliferation. Cell cycling 
disturbances in individuals with schizophrenia are also sug-
gested by observations of altered proliferation of fibro-
blasts35 and olfactory biopsy cultures36 from patients with 
the disorder as well as reports of differential expression of 
cell cycle genes in postmortem brain samples from such pa-
tients.37,38 Although, to our knowledge, there are no pub-
lished data implicating cell cycle dysregulation in individ-
uals with Pitt–Hopkins syndrome, changes in neural 
progenitor proliferation in the developing neocortex could 
contribute to the severe intellectual deficits observed in 
 people with this  condition.
Limitations
We do not provide a detailed mechanistic explanation of how 
TCF4 knockdown alters human neural progenitor cell pro-
liferation. As a transcription factor, TCF4 will directly affect 
the expression of multiple genes. However, our gene expres-
sion data do not distinguish between those changes that arise 
from reduced binding of TCF4 at the gene locus or secondary 
consequences. Methods based on chromatin immunoprecipi-
tation (e.g., ChIP-Seq) will be crucial in determining the pri-
mary targets of TCF4, some of which might mediate the ef-
fects on cell proliferation we observe.
Conclusion
We have shown that knockdown of TCF4 causes downstream 
changes in gene expression and proliferation of human cortical 
progenitor cells. Early disturbances in TCF4 expression could 
Fig. 3: Decrease in cell proliferation markers in the CTX0E03 neural progenitor cell line in association with TCF4 small interfering RNA 
(siRNA) #1 and #2 conditions, as measured by high-content imaging. (A) Compared with the negative control siRNA condition, Ki67- 
positive cells were reduced by a mean of 33% in association with the TCF4 siRNA#1 condition (p < 0.001) and by a mean of 28% in associ-
ation with the TCF4 siRNA#2 condition (p = 0.010). (B) Compared with the negative control siRNA condition, BrdU-positive cells were re-
duced by a mean of 34% in association with the TCF4 siRNA#1 condition (p = 0.017) and by a mean of 35% in association with the TCF4 
siRNA#2 condition (p = 0.027); n = 12 per condition. Error bars represent standard errors of the mean. *p < 0.05, **p < 0.01, ***p < 0.001.
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therefore impact upon the development of the human neocor-
tex through effects on the number and/or subsequent differen-
tiation of certain populations of cortical progenitors, suggest-
ing a plausible neurobiological mechanism contributing to 
cognitive deficits in individuals with Pitt–Hopkins syndrome 
and risk for schizophrenia.
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